重大资产重组！688621复牌

Group 1 - The core point of the article is that Beijing Sunshine Nuohua Pharmaceutical Research Co., Ltd. is progressing with a major asset restructuring by acquiring 100% equity of Jiangsu Langyan Life Science Technology Co., Ltd. and will resume trading on May 13 [1][2] - The acquisition is expected to significantly enhance the company's industry competitiveness and profitability, as well as improve its strategic layout [1][2] - The transaction will allow the company to leverage its R&D advantages alongside Langyan Life's production and sales strengths, creating new profit growth points [1] Group 2 - The deal will expand the company's pharmaceutical industrial sector, establishing a "CRO + pharmaceutical industry" business layout, which is anticipated to become a key component of the company's main business [2] - Post-transaction, the company will directly hold 100% equity of Langyan Life, which will benefit its overall strategic implementation and enhance profitability [2] - This acquisition is expected to improve the company's core competitiveness and sustainable development capabilities [2]